Joana Torres

Joana Torres

Auto-generated profile, based on publicly available information

Joana Torres

Division of Gastroenterology, Hospital Beatriz Ângelo, Loures, Portugal

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 August 2022 in Journal of Crohn's and Colitis
Verified
Journal Article
Open access
PDF file
JTJoana Torres
Joana Torres
MCMaría Chaparro
María Chaparro
MJMette Julsgaard
Mette Julsgaard
KKKonstantinos Katsanos
Konstantinos Katsanos
ZZZuzana Zelinkova
Zuzana Zelinkova
CWC Janneke Van der Woude
C Janneke Van der Woude
Inflammatory bowel disease has a high incidence and prevalence especially in young individuals in their reproductive years. Trying to conceive and being pregnant is an emotional period for those involved. In the majority of patients suffering from inflammatory bowel disease, maintenance therapy is required during pregnancy to control the disease, and disease control might necessitate introduction of new drugs during a vulnerable period. Therefore, the management of patients with a wish to conceive and during pregnancy requires specialized counselling and appropriate management including a multidisciplinary approach and close involvement of the prospective parents under a shared decision-making model. This updated consensus paper addresses these issues and is aimed to optimize pre-conceptional, pregnancy and post pregnancy counselling, including the monitoring and therapeutic management of patients with IBD patients with a wish to conceive.

1 July 2020 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
JTJoana Torres
Joana Torres
FPFrancesca Petralia
Francesca Petralia
TSTakahiro Sato
Takahiro Sato
PWPei Wang
Pei Wang
STShannon E. Telesco
Shannon E. Telesco
JCJean-Frederic Colombel
Jean-Frederic Colombel

29 April 2019 in Gut
Verified
Journal Article
Closed access
PDF file
JTJoana Torres
Joana Torres
JHJianzhong Hu
Jianzhong Hu
ASAkihiro Seki
Akihiro Seki
CECaroline Eisele
Caroline Eisele
NNNilendra Nair
Nilendra Nair
IPInga Peter
Inga Peter
Background and aims: Prenatal and early life bacterial colonisation is thought to play a major role in shaping the immune system. Furthermore, accumulating evidence links early life exposures to the risk of developing IBD later in life. We aimed to assess the effect of maternal IBD on the composition of the microbiome during pregnancy and on the offspring’s microbiome. Methods: We prospectively examined the diversity and taxonomy of the microbiome of pregnant women with and without IBD and their babies at multiple time points. We evaluated the role of maternal IBD diagnosis, the mode of delivery, antibiotic use and feeding behaviour on the microbiome composition during early life. To assess the effects of IBD-associated maternal and infant microbiota on the enteric immune system, we inoculated germ-free mice (GFM) with the respective stool and profiled adaptive and innate immune cell populations in the murine intestines. Results: Pregnant women with IBD and their offspring presented with lower bacterial diversity and altered bacterial composition compared with control women and their babies. Maternal IBD was the main predictor of the microbiota diversity in the infant gut at 7, 14, 30, 60 and 90 days of life. Babies born to mothers with IBD demonstrated enrichment in Gammaproteobacteria and depletion in Bifidobacteria. Finally, GFM inoculated with third trimester IBD mother and 90-day infant stools showed significantly reduced microbial diversity and fewer class-switched memory B cells and regulatory T cells in the colon. Conclusion: Aberrant gut microbiota composition persists during pregnancy with IBD and alters the bacterial diversity and abundance in the infant stool. The dysbiotic microbiota triggered abnormal imprinting of the intestinal immune system in GFM.

1 June 2021 in eClinicalMedicine
Verified
Journal Article
Open access
MAManasi Agrawal
Manasi Agrawal
JSJoão Sabino
João Sabino
CFCatarina Frias-Gomes
Catarina Frias-Gomes
CHChristen M. Hillenbrand
Christen M. Hillenbrand
CSCeline Soudant
Celine Soudant
JTJoana Torres
Joana Torres
Early life exposures impact immune system development and therefore the risk of immune-mediated diseases, including inflammatory bowel disease (IBD). We systematically reviewed the impact of pre-, peri‑, and postnatal exposures up to the age of five years on subsequent IBD diagnosis. We identified case-control and cohort studies reporting on the association between early life environmental factors and Crohn's disease (CD), ulcerative colitis (UC), or IBD overall. Databases were search from their inception until May 24th, 2019 until July 14th, 2020. We conducted meta-analyses for quantitative review of relevant risk factors that were comparable across studies and qualitative synthesis of the literature for a wide range of early life exposures, including maternal health and exposures during pregnancy, perinatal factors, birth month and related-factors, breastfeeding, hygiene-related factors and social factors, immigration, antibiotics, offspring health, including infections, and passive smoking. PROSPERO registration: CRD42019134980. Prenatal exposure to antibiotics (OR 1.8; 95% CI 1.2–2.5) and tobacco smoke (OR 1.5; 95% CI 1.2–1.9), and early life otitis media (OR 2.1; 95% CI 1.2–3.6) were associated with IBD. There was a trend towards an association between exposure to antibiotics in infancy and IBD (OR: 1.7, 95% CI 0.97, 2.9), supported by positive data on population-based data. Breastfeeding was protective against IBD. Other early life risk factors had no association with IBD, but data were limited and heterogenous. Early life is an important period of susceptibility for IBD development later in life. Tobacco smoke, infections and antibiotics were associated positively, and breastfeeding was associated negatively with IBD. Our findings offer an opportunity to develop primary prevention strategies. This study did not receive any funding.

4 August 2022 in Gut
Verified
Journal Article
Open access
PDF file
JRJordi Rimola
Jordi Rimola
JTJoana Torres
Joana Torres
SKShankar Kumar
Shankar Kumar
STStuart A. Taylor
Stuart A. Taylor
TKTorsten Kucharzik
Torsten Kucharzik
Endoscopy remains the reference standard for the diagnosis and assessment of patients with inflammatory bowel disease (IBD), but it has several important limitations. Cross-sectional imaging techniques such as magnetic resonance enterography (MRE) and intestinal ultrasound (IUS) are better tolerated and safer. Moreover, they can examine the entire bowel, even in patients with stenoses and/or severe inflammation. A variety of cross-sectional imaging activity scores strongly correlate with endoscopic measures of mucosal inflammation in the colon and terminal ileum. Unlike endoscopy, cross-sectional techniques allow complete visualisation of the small-bowel and assess for extraintestinal disease, which occurs in nearly half of patients with IBD. Extramural findings may predict outcomes better than endoscopic mucosal assessment, so cross-sectional techniques might help identify more relevant therapeutic targets. Coupled with their high sensitivity, these advantages have made MRE and IUS the primary non-invasive options for diagnosing and monitoring Crohn’s disease; they are appropriate first-line investigations, and have become viable alternatives to colonoscopy. This review discusses cross-sectional imaging in IBD in current clinical practice as well as research lines that will define the future role of these techniques.

10 November 2023 in Nature Reviews Gastroenterology & Hepatology
Verified
Journal Article
Closed access
PDF file
JRJonas J. Rudbaek
Jonas J. Rudbaek
MAManasi Agrawal
Manasi Agrawal
JTJoana Torres
Joana Torres
SMSaurabh Mehandru
Saurabh Mehandru
JCJean-Frederic Colombel
Jean-Frederic Colombel
TJTine Jess
Tine Jess